Comparative Pharmacology
Head-to-head clinical analysis: ISOPTO CETAMIDE versus OPTOMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISOPTO CETAMIDE versus OPTOMYCIN.
ISOPTO CETAMIDE vs OPTOMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfacetamide inhibits bacterial dihydropteroate synthase, disrupting folic acid synthesis and thereby inhibiting bacterial growth.
Optomycin is a semi-synthetic glycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of the peptidoglycan precursor, preventing transpeptidation and cross-linking.
1-2 drops into conjunctival sac every 2-3 hours initially, then taper as infection resolves. Ophthalmic suspension (10% or 30%).
1.5 mg/kg IV every 8 hours; alternatively, 5-7 mg/kg IV daily.
None Documented
None Documented
Terminal elimination half-life of sodium sulfacetamide is 7-12 hours in normal renal function; prolonged in renal impairment.
3-5 hours (terminal half-life); prolonged to 10-20 hours in renal impairment.
Primarily renal (sodium sulfacetamide excreted unchanged in urine, ~85% within 24 hours). Minor biliary/fecal elimination.
Renal: 75-90% unchanged; biliary: 5-10%; fecal: <5%.
Category C
Category C
Ophthalmic Antibiotic
Ophthalmic Antibiotic/Corticosteroid Combination